NCT04624633 2026-02-25Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLLDana-Farber Cancer InstitutePhase 2 Active not recruiting29 enrolled 9 charts
NCT04783415 2024-12-02Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell LymphomaCity of Hope Medical CenterPhase 2 Active not recruiting12 enrolled 8 charts